Brazilian chronic myeloid leukemia working group recommendations for discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia in clinical practice

Página do item simplificado
dc.creatorCarla Boquimpani
dc.creatorFernanda Salles Seguro
dc.creatorGustavo Henrique Romani Magalhães
dc.creatorIngrid Luise Soares Pinto
dc.creatorIsrael Bendit
dc.creatorJaisson André Pagnoncelli Bortolini
dc.creatorKatia Borgia Barbosa Pagnano
dc.creatorRenato Centrone
dc.creatorVaneuza Funke
dc.date.accessioned2023-12-06T19:27:39Z
dc.date.accessioned2025-09-08T23:10:18Z
dc.date.available2023-12-06T19:27:39Z
dc.date.issued2022
dc.format.mimetypepdf
dc.identifier.doihttps://doi.org/10.1016/j.htct.2022.04.002
dc.identifier.issn2531-1379
dc.identifier.urihttps://hdl.handle.net/1843/61801
dc.languageeng
dc.publisherUniversidade Federal de Minas Gerais
dc.relation.ispartofHematology, Transfusion and Cell Therapy
dc.rightsAcesso Aberto
dc.subjectNeoplasias
dc.subjectGuia de Prática Clínica
dc.subjectTerapêutica
dc.subject.otherPractice guideline
dc.subject.otherLeukemia myelogenous chronic
dc.subject.otherBCR-ABL positive
dc.subject.otherTherapeutics
dc.titleBrazilian chronic myeloid leukemia working group recommendations for discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia in clinical practice
dc.typeArtigo de periódico
local.citation.epage409
local.citation.issue3
local.citation.spage402
local.citation.volume44
local.description.resumoIntroduction Treatment-free remission (TFR) is a new goal of chronic myeloid leukemia (CML) therapy. TFR is feasible when the patient has achieved a deep and stable molecular response and met the criteria required to ensure its success. Treatment discontinuation should not be proposed to the CML patient if minimum conditions are not met. In Brazil, for example, molecular tests (BCR::ABL1) are not broadly available, making it difficult to monitor the patients adequately. Objective In this sense, providing TFR recommendations for Brazilian physicians are therefore necessary. These recommendations include the main criteria checklist to start the TKIs treatment discontinuing process in patients diagnosed with CML and the population-eligible characteristics for treatment discontinuation. Method Age, risk score at diagnosis, TKI treatment duration, BCR::ABL1 transcripts type, depth of the molecular response for treatment discontinuation, treatment adherence, patient monitoring and withdrawal syndrome are essential factors to consider in TFR. After TKI discontinuation, BCR::ABL1 transcripts monitoring should be more frequent. When a major molecular response loss is observed during the monitoring of a patient in TFR, the TKI treatment should be resumed.
local.identifier.orcidhttp://orcid.org/0000-0001-7396-2495
local.identifier.orcidhttp://orcid.org/0000-0001-6637-3588
local.identifier.orcidhttp://orcid.org/0000-0001-5393-8041
local.identifier.orcidhttp://orcid.org/0000-0002-1891-464X
local.identifier.orcidhttp://orcid.org/0000-0002-4751-1428
local.identifier.orcidhttp://orcid.org/0000-0001-7298-8570
local.identifier.orcidhttp://orcid.org/0000-0001-7975-0805
local.identifier.orcidhttp://orcid.org/0000-0002-7145-2552
local.identifier.orcidhttp://orcid.org/0000-0002-2122-7277
local.publisher.countryBrasil
local.publisher.departmentMEDICINA - FACULDADE DE MEDICINA
local.publisher.initialsUFMG
local.url.externahttps://www.sciencedirect.com/science/article/pii/S2531137922000505?via%3Dihub

Arquivos

Pacote original

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
Brazilian chronic myeloid leukemia working group recommendations for discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia in clinical practice.pdf
Tamanho:
360.48 KB
Formato:
Adobe Portable Document Format
Baixar

Licença do pacote

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
License.txt
Tamanho:
1.99 KB
Formato:
Plain Text
Descrição:
Baixar

Coleções

Artigo de Periódico

Logo UFMG